Dr. Saphire uses structural biology techniques, including crystallography and cryo-electron microscopy, to image and explain why some of the world’s most deadly viruses, including Ebola virus and Lassa virus, are pathogenic. Her team determined three-dimensional structures for the surface glycoproteins of multiple pathogenic viruses, both alone and in complex with protective antibodies. As one example, their work on Lassa virus forms the basis for international efforts to develop and evaluate Lassa virus vaccines.

In 2013, Dr. Saphire spearheaded the Viral Hemorrhagic Fever Immunotherapeutic Consortium (VIC), a five-continent collaboration that profiled hundreds of antibodies against viruses like Ebola and Lassa to determine which antibody features correlate with protection in vivo. The VIC provided the foundation for the development of effective therapeutic antibody cocktails to treat individuals suffering from Ebola virus infection. The success of the VIC serves as a model for the CoVIC.

The Peters lab develops computational tools to address fundamental questions in immunology.  In addition to characterizing targets of immune responses, termed epitopes, and designing algorithms to compare differences in immune responses between healthy individuals and those affected by various diseases, Dr. Peters teamed with Dr. Alessandro Sette to generate the Immune Epitope Database (IEDB)–a catalog of all published experiments describing immune epitope recognition. The IEDB transforms free text information from published papers into a searchable, structured format that enhances its usability and connects to other information resources.

Dr. Georgia Tomaras is a tenured Professor of Surgery, Professor of Immunology, Professor of Molecular Genetics and Microbiology at Duke University, and is a Fellow of the American Academy of Microbiology (AAM) and a Fellow of the American Association for the Advancement of Science (AAAS).

Her primary research focus is the study of human immunity and identification of immune correlates of protection against infectious diseases. To effectively bridge basic and translational science, Dr. Tomaras’ laboratory has established a longstanding good clinical laboratory practice (GCLP) environment for experimental and data management. The Tomaras laboratory established the binding antibody multiplex assay (BAMA) for high-throughput, simultaneous evaluation of multiple antigens to profile antibody isotypes and subclasses; high throughput biophysical methods to determine polyclonal antibody avidity and monoclonal antibody specificity and avidity; and methods to interrogate the repertoire of antibody Fc effector functions.